Karin C Nitiss, Matthew Gilbertson, Maureen N McCoy, Abhishek Deshpande, Anh T Q Cong, Hannah Miles, Viraj Shah, Kim Cuaresma, Matthew J Schellenberg, John L Nitiss
{"title":"Determinants of Etoposide Hypersensitivity Span All of the Top2 Alpha Catalytic Domains.","authors":"Karin C Nitiss, Matthew Gilbertson, Maureen N McCoy, Abhishek Deshpande, Anh T Q Cong, Hannah Miles, Viraj Shah, Kim Cuaresma, Matthew J Schellenberg, John L Nitiss","doi":"10.1016/j.jmb.2026.170068","DOIUrl":null,"url":null,"abstract":"<p><p>Type II topoisomerases are found in all kingdoms of life and perform key biological functions during replication, transcription, and other DNA metabolic events. These enzymes are also the targets of important classes of anti-bacterial and anti-cancer drugs. Clinically active drugs targeting topoisomerase II primarily act as poisons rather than as enzyme inhibitors. During the normal enzymatic reaction, topoisomerase poisons stabilize the normally reversible covalent enzyme/DNA adduct leading to DNA damage. More recently, Top2 mutants have been identified that exert the same effect as these small molecules, and expression of these mutants in cells leads to genome instability. Mutations that increase the potency of topoisomerase targeting drugs have the potential to mimic drug action and expand insight into the drug mechanism. Here we carried out an extensive screen of mutations in human Top2α to identify mutations that result in elevated levels of sensitivity to the anti-cancer drug etoposide. This screen was conducted by expressing a library of mutagenized human Top2α that complemented a yeast temperature sensitive Top2 allele in rad52- yeast strains. Etoposide hypersensitive mutations were identified throughout the catalytic domains of Top2α. Mutants were typically hypersensitive to other Top2 inhibitors, although some mutants had hypersensitivity that was specific for etoposide. Several examples of mutant proteins identified in the screen were purified and characterized biochemically. These proteins exhibited a broad range of alterations in enzyme activity including altered requirements for divalent cations, altered relaxation and decatenation activity, altered utilization of ATP, and enhanced DNA cleavage in the absence of inhibitors. Our results suggest that diverse mechanisms influence the ability of small molecules to convert type II topoisomerases to DNA damaging agents, and the etoposide hypersensitivity mutations found provide landmarks for the development of small molecules with improved potency.</p>","PeriodicalId":369,"journal":{"name":"Journal of Molecular Biology","volume":" ","pages":"170068"},"PeriodicalIF":4.7000,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Molecular Biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.jmb.2026.170068","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Type II topoisomerases are found in all kingdoms of life and perform key biological functions during replication, transcription, and other DNA metabolic events. These enzymes are also the targets of important classes of anti-bacterial and anti-cancer drugs. Clinically active drugs targeting topoisomerase II primarily act as poisons rather than as enzyme inhibitors. During the normal enzymatic reaction, topoisomerase poisons stabilize the normally reversible covalent enzyme/DNA adduct leading to DNA damage. More recently, Top2 mutants have been identified that exert the same effect as these small molecules, and expression of these mutants in cells leads to genome instability. Mutations that increase the potency of topoisomerase targeting drugs have the potential to mimic drug action and expand insight into the drug mechanism. Here we carried out an extensive screen of mutations in human Top2α to identify mutations that result in elevated levels of sensitivity to the anti-cancer drug etoposide. This screen was conducted by expressing a library of mutagenized human Top2α that complemented a yeast temperature sensitive Top2 allele in rad52- yeast strains. Etoposide hypersensitive mutations were identified throughout the catalytic domains of Top2α. Mutants were typically hypersensitive to other Top2 inhibitors, although some mutants had hypersensitivity that was specific for etoposide. Several examples of mutant proteins identified in the screen were purified and characterized biochemically. These proteins exhibited a broad range of alterations in enzyme activity including altered requirements for divalent cations, altered relaxation and decatenation activity, altered utilization of ATP, and enhanced DNA cleavage in the absence of inhibitors. Our results suggest that diverse mechanisms influence the ability of small molecules to convert type II topoisomerases to DNA damaging agents, and the etoposide hypersensitivity mutations found provide landmarks for the development of small molecules with improved potency.
期刊介绍:
Journal of Molecular Biology (JMB) provides high quality, comprehensive and broad coverage in all areas of molecular biology. The journal publishes original scientific research papers that provide mechanistic and functional insights and report a significant advance to the field. The journal encourages the submission of multidisciplinary studies that use complementary experimental and computational approaches to address challenging biological questions.
Research areas include but are not limited to: Biomolecular interactions, signaling networks, systems biology; Cell cycle, cell growth, cell differentiation; Cell death, autophagy; Cell signaling and regulation; Chemical biology; Computational biology, in combination with experimental studies; DNA replication, repair, and recombination; Development, regenerative biology, mechanistic and functional studies of stem cells; Epigenetics, chromatin structure and function; Gene expression; Membrane processes, cell surface proteins and cell-cell interactions; Methodological advances, both experimental and theoretical, including databases; Microbiology, virology, and interactions with the host or environment; Microbiota mechanistic and functional studies; Nuclear organization; Post-translational modifications, proteomics; Processing and function of biologically important macromolecules and complexes; Molecular basis of disease; RNA processing, structure and functions of non-coding RNAs, transcription; Sorting, spatiotemporal organization, trafficking; Structural biology; Synthetic biology; Translation, protein folding, chaperones, protein degradation and quality control.